Women’s health diagnostics company Nanopath has raised $25 million in a Series B to scale its rapid vaginal health testing platform.
The round was led by Norwest Ventures and SV Health Investors’ MedTech Convergence Fund, with strategic participation from the Labcorp Venture Fund, with participation from Elderberry Ventures, GingerBread Capital, and Alumni Ventures.
Nanopath has developed a point-of-care diagnostics platform using proprietary optical biosensing technology to detect molecular targets without nucleic acid amplification. Its tests can diagnose vaginitis in as little as 15 minutes at the point of care, without requiring samples to be sent to an external laboratory.
Alongside the raise, Elderberry Ventures’ Managing Partner Catherine Kiani, J.D and Labcorp Diagnostics Vice President Mindy Nye, Ph.D. have joined Nanopath’s Board of Advisors as Observers.
The funding will support manufacturing scale-up, team expansion, and preparations for commercialization. Nanopath also plans to launch an FDA 510(k) study in 2028, targeting approximately 1,500 patients across 10 to 15 sites.
Beyond vaginitis, the company is exploring applications for sexually transmitted infections (STIs) and urinary tract infections (UTIs).
“We’ve spent years developing and pressure-testing a fundamentally new approach to molecular diagnostics for patients who have been overlooked for far too long,” said Alison Burklund, Ph.D., Co-Founder & Co-CEO of Nanopath. “This funding brings us closer to the next and most important step – translating that innovation into meaningful clinical impact.”
